Fingolimod in RRMS: results from two trials


REPORT FROM THE 2009 AAN ANNUAL MEETING – Fingolimod (FTY720), a novel sphingosine 1-phosphate receptor modulator, appears to be effective in patients with relapsing-remitting MS, according to the results from a new phase III trial.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page